238 related articles for article (PubMed ID: 27108405)
1. Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial.
Sköldenberg O; Rysinska A; Eisler T; Salemyr M; Bodén H; Muren O
BMC Musculoskelet Disord; 2016 Apr; 17():174. PubMed ID: 27108405
[TBL] [Abstract][Full Text] [Related]
2. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
[TBL] [Abstract][Full Text] [Related]
3. Denosumab Prevents Early Periprosthetic Bone Loss After Uncemented Total Hip Arthroplasty: Results from a Randomized Placebo-Controlled Clinical Trial.
Nyström A; Kiritopoulos D; Ullmark G; Sörensen J; Petrén-Mallmin M; Milbrink J; Hailer NP; Mallmin H
J Bone Miner Res; 2020 Feb; 35(2):239-247. PubMed ID: 31589776
[TBL] [Abstract][Full Text] [Related]
4. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
5. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.
Sköld C; Kultima K; Freyhult E; Larsson A; Gordh T; Hailer NP; Mallmin H
Osteoporos Int; 2022 Sep; 33(9):1-8. PubMed ID: 35608639
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
[TBL] [Abstract][Full Text] [Related]
8. Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty.
Nagoya S; Tateda K; Okazaki S; Kosukegawa I; Shimizu J; Yamashita T
Eur J Orthop Surg Traumatol; 2018 Dec; 28(8):1601-1607. PubMed ID: 29774416
[TBL] [Abstract][Full Text] [Related]
9. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Voskaridou E; Ntanasis-Stathopoulos I; Papaefstathiou A; Christoulas D; Dimopoulou M; Repa K; Papatheodorou A; Peppa M; Terpos E
Blood Adv; 2018 Nov; 2(21):2837-2847. PubMed ID: 30381400
[TBL] [Abstract][Full Text] [Related]
10. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
11. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
12. [Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study].
Nehme A; Maalouf G; Tricoire JL; Giordano G; Chiron P; Puget J
Rev Chir Orthop Reparatrice Appar Mot; 2003 Nov; 89(7):593-8. PubMed ID: 14699304
[TBL] [Abstract][Full Text] [Related]
13. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants.
Holding CA; Findlay DM; Stamenkov R; Neale SD; Lucas H; Dharmapatni AS; Callary SA; Shrestha KR; Atkins GJ; Howie DW; Haynes DR
Biomaterials; 2006 Oct; 27(30):5212-9. PubMed ID: 16806459
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
Lewiecki EM
Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
[TBL] [Abstract][Full Text] [Related]
15. Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial.
Kiritopoulos D; Nyström A; Ullmark G; Sörensen J; Petrén-Mallmin M; Milbrink J; Hailer NP; Mallmin H
Acta Orthop; 2022 Sep; 93():709-720. PubMed ID: 36069479
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
17. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
[TBL] [Abstract][Full Text] [Related]
18. No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial.
Muren O; Akbarian E; Salemyr M; Bodén H; Eisler T; Stark A; Sköldenberg O
Acta Orthop; 2015; 86(5):569-74. PubMed ID: 25885280
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
[TBL] [Abstract][Full Text] [Related]
20. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
